Medical Morphine Market Research Report: Information By Route of Administration (Oral and Injectables), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, and Others), By Application (Myocardial Infarction, Diarrhea, Arthritis, Kidney Stones, Cancer, and Others), By End User (Hospitals and Clinics, Ambulatory Surgical Centers, and Home Care), and By Region (North America, Europe, Asia-Pacific, and Rest Of The World) – Market Forecast Till 2032

Global Medical Morphine Market Overview

Medical Morphine Market Size was valued at USD 21.5 Billion in 2022. The Medical Morphine market industry is projected to grow from USD 23.1 Billion in 2023 to USD 40.2 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.20% during the forecast period (2023 - 2032).The prevalence of orthopaedic conditions and chronic pain is rising, and there are more palliative care facilities and more people using morphine for pain management, are the key market drivers enhancing the market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Medical Morphine Market Trends

• The increase in prescription of painkillers for different illnesses is driving the market growth

The market expansion is anticipated to be accelerated by the rise in the prescription of painkillers for a variety of conditions, including cancer, cardiovascular problems, and arthritis. The ageing population's vulnerability and their associated medical issues are also expected to support the expansion of the medical morphine industry. Additionally, it is anticipated that the growing patient population and the quickening rate of market participant penetration will fuel market expansion. Additionally, it is anticipated that the rising prevalence of cancer and other ailments, including cardiovascular conditions and others, would have an impact on the worldwide medical morphine market's expansion. The increased usage of morphine as a pain reliever is a major driver of the market's expansion. One of the most effective forms of pain relief is morphine. Additionally, the majority of places throughout the world authorise its usage in the treatment of severe and persistent pain linked to a sophisticated medical condition. Additionally, the main factor fueling the growth of the medical morphine market value is the rising prevalence of orthopaedic conditions like elbow pain, arthritis, fibromyalgia, and osteoporosis.

One of the most effective medications for treating pain is morphine. Furthermore, it is generally accepted that its usage in the treatment of severe and persistent pain that is linked to serious medical conditions is normal practise. In addition, the key cause of the rising growth of the morphine market is the increasing prevalence of orthopaedic ailments such as osteoporosis, fibromyalgia, elbow pain, and arthritis. According to the World Health Organization's February 2021 update, 1.71 billion people worldwide suffer from musculoskeletal problems. The majority of people, 568 million, suffer from low back discomfort, which is the most common type. The need for its therapies is being driven by the fact that musculoskeletal disorders are one of the main causes of disability worldwide, which is propelling the morphine market's expansion during the study period.

Osteoarthritis afflicted more than 32.5 million Americans in 2020, according to the Centres for Disease Control and Prevention. Osteoarthritis prevalence is rising gradually in the United Kingdom. Moreover, older people are more likely to have pain from orthopaedic illnesses. Therefore, the anticipated increase in the number of elderly people will contribute to the market's expansion over the study period. The examined market is therefore anticipated to be highly driven during the study period as a result of the aforementioned factors. The demand for opioids has also been positively impacted by the rising number of people having surgeries, particularly for managing post-operative pain, promoting quick healing, and decreasing patient problems. In addition, generic manufacturers' increased emphasis on the abuse-deterrent formulation (ADF) has led to the development of new opioid variations, which has increased demand for them as potent painkillers. Thus, driving the Medical Morphine market revenue.

Medical Morphine Market Segment Insights

Medical Morphine Route of Administration Insights

The Medical Morphine market segmentation, based on route of administration, includes Oral and Injectables. Injectables segment dominated the market in 2022. This is because of its long-lasting impact and quick pain alleviation. Additionally, the prevalence of neurological illnesses and the chronic pain that goes along with them has increased the need for medications that provide immediate pain relief, which has increased demand for the injectable market segment. For instance, according to Medline, 12% of Americans suffer from migraines.

Medical Morphine Distribution Channel Insights

The Medical Morphine market segmentation, based on distribution channel, includes Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, and Others. Online pharmacy segment dominated the market in 2022. This is primarily because the healthcare industry is adopting IoTs quickly, and rising internet penetration has allowed the segment to have strong segmental growth over the course of the projected period. 6.6% of the world's population, or 5.25 billion people, use the internet, and that number is anticipated to rise in the future.

Medical Morphine Application Insights

The Medical Morphine market segmentation, based on application, includes Myocardial Infarction, Diarrhea, Arthritis, Kidney Stones, Cancer, and Others. Cancer segment dominated the Medical Morphine market in 2022.This is mostly a result of the rise in cancer cases, which cause the onset of chronic pain. For instance, according to the WHO, cancer will account for approximately 10 million deaths worldwide in 2020.

Medical Morphine End User Insights

The Medical Morphine market segmentation, based on end user, includes Hospitals and Clinics, Ambulatory Surgical Centers, and Home Care. Hospitals and clinics segment dominated the Medical Morphine market in 2022.This is due to the simple accessibility of medications in clinics and hospitals. The CDC estimates that 142.81 million morphine prescriptions were recorded in the U.S. in 2020, with a dispensing rate of 43.3 pills per 100 people. As a result, it is projected that high prescriptions will segment increase.

Figure 1: Medical Morphine Market, by End User, 2022 & 2032 (USD Billion) 

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Medical Morphine Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Medical Morphine Market dominated this market in 2022 (45.80%). The presence of major players, the high frequency of chronic diseases in the area, and the developed healthcare infrastructure are only a few of the important aspects responsible for the market's growth.Further, the U.S. Medical Morphine market held the largest market share, and the Canada Medical Morphine market was the fastest growing market in the North America region.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: MEDICAL MORPHINE MARKET SHARE BY REGION 2022 (USD Billion) 

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Medical Morphine market accounted for the healthy market share in 2022. Some of the factors that are anticipated to accelerate market growth include advantageous government initiatives and an increase in the number of research partnerships.Further, the German Medical Morphine market held the largest market share, and the U.K Medical Morphine market was the fastest growing market in the European region.

The Asia Pacific Medical Morphine market is expected to register significant growth from 2023 to 2032. One of the main drivers of market expansion is the increasing prevalence of chronic diseases including cardiovascular issues. Because of its growing population, larger patient pool, and easy access to cutting-edge treatments, China is expected to have the quickest growth. The Asia Pacific medical morphine market is expanding as a result of higher health spending in the region. Moreover, China’s Medical Morphine market held the largest market share and the Indian Medical Morphine market was the fastest growing market in the Asia-Pacific region.

Medical Morphine Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Medical Morphine market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Medical Morphine industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Medical Morphine industry to benefit clients and increase the market sector. In recent years, the Medical Morphine industry has offered some of the most significant advantages to medicine. Major players in the Medical Morphine market, including Alcaliber S.A Pfizer Inc., Sun Pharmaceutical Industries Ltd., Taj Pharmaceuticals Limited, MANUS AKTTEVA BIOPHARMA LLP, Mallinckrodt Pharmaceuticals, Purdue Pharma L.P., Johnson Matthey Fine Chemicals, Verve Health Care Ltd., and NORTHEAST PHARM, are attempting to increase market demand by investing in research and development Route of Administrations.

A specialised pharmaceutical firm called Amphastar Pharmaceuticals Inc. (Amphastar) creates, produces, and sells both generic and brand-name injectable, intranasal, and inhalation medications. It offers pharmaceutical goods with insulin as an active ingredient. Enoxaparin sodium injection, cosyntropin for injection, naloxone hydrochloride (HCl) injection, phytonadione injection, lidocaine jelly, amphadase hyaluronidase injection, epinephrine, naloxone, phytonadione, primatene mist, and glucagon are some of the company's main products. Amphastar sells its goods to long-term care facilities, hospitals, clinics, and other alternative care locations. In the US, the UK, France, and China, the corporation markets its products through subsidiaries, specialty distributors, wholesalers, and retailers. US state of California's Rancho Cucamonga serves as the home base for Amphastar. Amphastar Pharmaceuticals (US) received FDA approval for its injection of morphine sulphate in May 2021.

Pharmaceutical business Purdue Pharma LP (Purdue) creates pharmacologic medicines for the treatment and management of pain. The business engages in the development, production, and marketing of both prescription and over-the-counter (OTC) medications as well as other healthcare-related items. Prescription opioids, sedatives for sleep problems, laxatives, antiseptics, and dietary supplements are some of its main product categories. Butrans, Hysingla, OxyContin, Senokot, Colace, Peri-Colace, Betadine, and SlowMag are among the items it sells. The business also conducts clinical research on recently released medications and investigational drugs. The business has facilities in New Jersey and North Carolina. In the US, Stamford, Connecticut, serves as the home office for Purdue. An improved version of buprenorphine that reduces cravings and is used to treat opioid addiction, including OxyContin addiction, was patented by Purdue Pharma (US) in September 2018.

Key Companies in the Medical Morphine market include

• 
  

  Alcaliber S.A Pfizer Inc.

  
  


• 
  

  Sun Pharmaceutical Industries Ltd.

  
  


• 
  

  Taj Pharmaceuticals Limited

  
  


• 
  

  MANUS AKTTEVA BIOPHARMA LLP

  
  


• 
  

  Mallinckrodt Pharmaceuticals

  
  


• 
  

  Purdue Pharma L.P.

  
  


• 
  

  Johnson Matthey Fine Chemicals

  
  


• 
  

  Verve Health Care Ltd.

  
  


• 
  

  NORTHEAST PHARM

  
  

Medical Morphine Industry Developments

May 2022:To address the opioid crisis and find and develop cutting-edge therapies for the management of chronic pain, researchers from the Oklahoma State University Centre for Health Sciences and the University of Arizona Health Sciences have formed a creative alliance.

October 2021:The Corydalis yanhusuo plant extract reverses opiate addiction while also preventing morphine tolerance and dependency, according to research conducted at the University of California, Irvine.

Medical Morphine Market Segmentation

Medical Morphine Route of Administration Outlook

• 
  

  Oral

  
  


• 
  

  Injectables

  
  

Medical Morphine Distribution Channel Outlook

• 
  

  Hospital Pharmacy

  
  


• 
  

  Online Pharmacy

  
  


• 
  

  Retail Pharmacy

  
  


• 
  

  Others

  
  

Medical Morphine Application Outlook

• 
  

  Myocardial Infarction

  
  


• 
  

  Diarrhea

  
  


• 
  

  Arthritis

  
  


• 
  

  Kidney Stones

  
  


• 
  

  Cancer

  
  


• 
  

  Others

  
  

Medical Morphine End User Outlook

• 
  

  Hospitals and Clinics

  
  


• 
  

  Ambulatory Surgical Centers

  
  


• 
  

  Home Care

  
  

Medical Morphine Regional Outlook

• 
  

  North America

  
  

• 
  

  U.S.

  
  


• 
  

  Canada

  
  

• 
  

  Europe

  
  

• 
  

  Germany

  
  


• 
  

  France

  
  


• 
  

  UK

  
  


• 
  

  Italy

  
  


• 
  

  Spain

  
  


• 
  

  Rest of Europe

  
  

• 
  

  Asia-Pacific

  
  
  
  
  • 
    

    China

    
    
  
  
  • 
    

    Japan

    
    
  
  
  • 
    

    India

    
    
  
  
  • 
    

    Australia

    
    
  
  
  • 
    

    South Korea

    
    
  
  
  • 
    

    Australia

    
    
  
  
  • 
    

    Rest of Asia-Pacific

    
    
  
  
  
  


• 
  

  Rest of the World

  
  
  
  
  • 
    

    Middle East

    
    
  
  
  • 
    

    Africa

    
    
  
  
  • 
    

    Latin America

    
    
  
  
  
  

Report Scope:

Report Attribute/Metric	Details
Market Size 2022	USD 21.5 Billion
Market Size 2023	USD 23.1 Billion
Market Size 2032	USD 40.2 Billion
Compound Annual Growth Rate (CAGR)	7.20% (2023-2032)
Base Year	2022
Market Forecast Period	2023-2032
Historical Data	2018- 2022
Market Forecast Units	Value (USD Billion)
Report Coverage	Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
Segments Covered	Route of Administration, Distribution Channel, Application, End User, and Region
Geographies Covered	North America, Europe, Asia Pacific, and the Rest of the World
Countries Covered	The U.S., Canada, German, France, U.K, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
Key Companies Profiled	Alcaliber S.A Pfizer Inc., Sun Pharmaceutical Industries Ltd., Taj Pharmaceuticals Limited, MANUS AKTTEVA BIOPHARMA LLP, Mallinckrodt Pharmaceuticals, Purdue Pharma L.P., Johnson Matthey Fine Chemicals, Verve Health Care Ltd., and NORTHEAST PHARM
Key Market Opportunities	Rapid rise in awareness regarding treatment and technological advancements
Key Market Dynamics	The rising prevalence of orthopedic diseases and chronic pain, increasing palliative care facilities, and the rise in the usage of morphine for pain management

Frequently Asked Questions (FAQ) :